Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluminate-5: elecoglipron plus dapagliflozin versus elecoglipron alone or dapagliflozin alone in adults with type 2 diabetes mellitus
CTR20263390Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Elecoglipron + dapagliflozin, Elecoglipron monotherapy and Dapagliflozin monotherapy (3 arms). Primary endpoint: Change from baseline in HbA1c. Started Jul 2026; status: active.
02
Drugs
elecogliprondapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263390.